StockData

uniQure vs Wave Life Sciences

QURE and WVE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How QURE and WVE compare

uniQure is the larger company, worth 2.6 times as much as Wave Life Sciences ($1.4B against $560M).

Wave Life Sciences keeps more of each dollar of sales as profit, with a net margin of −297% compared with −1351% at uniQure.

Wave Life Sciences scores higher on the StockData Score (10 against 4 for uniQure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricQUREWVE
Size and price
Market cap$1.4B$560M
Share price$20.78$2.84
Change, 1 year−30.5%−59.9%
Change, 5 years−27.9%−28.8%
Beta (5Y)3.141.86
Employees221317
StockData Score
Total score410 (better)
Valuation score03 (better)
Growth score2 (better)1
Performance score01 (better)
Health score25 (better)
Dividend score00
Valuation
P/S77.2×7.9× (better)
P/B4.4×1.4× (better)
FCF yield−11.2% (better)−37.2%
Fair value$6.42$5.23
Margin of safety−224%45.7% (better)
Growth
Revenue growth (TTM)30.2%–
Revenue growth, 5Y average−15.6%16.3% (better)
Profitability
Gross margin92.5%–
Operating margin−1072%−321% (better)
Net margin−1351%−297% (better)
FCF margin−865%−294% (better)
Return on equity−158%−80.0% (better)
Financial health
Debt / equity0.15 (better)0.00
Interest coverage−3.4×–
Current ratio10.01 (better)8.38
Altman Z-score−0.51 (better)−1.30
Piotroski F-score4 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions96.0%92.6%
Held by insiders2.1%23.1%
Insider net buying, 12 months−$20.2M$66.5M (better)
Superinvestors holding–1
Short interest, % of float12.5%13.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.